Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Current Assets (2016 - 2025)

Sonoma Pharmaceuticals has reported Current Assets over the past 15 years, most recently at $12.1 million for Q4 2025.

  • For Q4 2025, Current Assets fell 1.9% year-over-year to $12.1 million; the TTM value through Dec 2025 reached $12.1 million, down 1.9%, while the annual FY2025 figure was $12.6 million, 0.8% up from the prior year.
  • Current Assets for Q4 2025 was $12.1 million at Sonoma Pharmaceuticals, down from $12.5 million in the prior quarter.
  • Over five years, Current Assets peaked at $18.0 million in Q3 2021 and troughed at $11.2 million in Q4 2022.
  • A 5-year average of $13.3 million and a median of $12.5 million in 2023 define the central range for Current Assets.
  • On a YoY basis, Current Assets climbed as much as 26.55% in 2022 and fell as far as 36.54% in 2022.
  • Year by year, Current Assets stood at $17.7 million in 2021, then tumbled by 36.54% to $11.2 million in 2022, then rose by 11.31% to $12.5 million in 2023, then dropped by 0.98% to $12.4 million in 2024, then fell by 1.9% to $12.1 million in 2025.
  • Business Quant data shows Current Assets for SNOA at $12.1 million in Q4 2025, $12.5 million in Q3 2025, and $13.1 million in Q2 2025.